Key result
Combining angiotensin-receptor blockers with angiotensin-converting-enzyme inhibitors increases the risk of adverse drug effects and treatment discontinuation compared to monotherapy, though it remains a viable option for select patients with persistent heart failure symptoms.
Why the study?
Does combining angiotensin-receptor blockers with angiotensin-converting-enzyme inhibitors increase adverse drug effects compared to ACE inhibitors alone?
Does combining angiotensin-receptor blockers with angiotensin-converting-enzyme inhibitors increase adverse drug effects compared to ACE inhibitors alone?
Answers are grounded in this paper and cite their sources.
While combining ACE inhibitors with ARBs is recommended for specific patients with symptomatic HFrEF, it is associated with increased risks of renal dysfunction and hyperkalemia, necessitating careful patient selection and monitoring.
See related research article by McAlister and colleagues at [www.cmaj.ca/cgi/doi/10.1503/cmaj.101333][1]. In this issue, McAlister and colleagues looked at the safety of combining angiotensin-receptor blockers with angiotensin-converting-enzyme (ACE) inhibitors (combination therapy) using a
No takes yet. Share an insight, caveat, or question.
Christopher O. Phillips (2011) conducted an editorial in Heart failure, left ventricular dysfunction, and chronic kidney disease. Combination therapy (angiotensin-receptor blockers and angiotensin-converting-enzyme inhibitors) vs. ACE inhibitor monotherapy was evaluated. Combining angiotensin-receptor blockers with angiotensin-converting-enzyme inhibitors increases the risk of adverse drug effects and treatment discontinuation compared to monotherapy, though it remains a viable option for select patients with persistent heart failure symptoms.
Synapse has enriched 10 related papers. Consider them for comparative context: